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Abstract
Metastasis, the spread and growth of tumor cells from the primary site to distant organs, is
arguably the most devastating and deadly attribute of cancer, and is ultimately responsible for
90% of cancer-related deaths. Circulating tumor cells (CTCs) are exceedingly rare cells found in
the whole blood of cancer patients which have the potential to serve as a 'blood biopsy'. The
intricate characterization of these cells could result in an entire new class of therapies directly
targeting metastasis.
Present technologies enable only a susbset of potential analyses to be conducted, principally due
to sub-optimal cell isolation sensitivity, purity, throughput, or handling method. Here, we present
two novel technologies to address the challenge of CTC isolation.
First, we build on affinity-based microfluidic cell capture platforms by developing sacrificial
hydrogel coatings to enable the innocuous release of captured cells; we demonstrate that model
CTCs captured from whole blood remain viable and proliferative following release and are
compatible with downstream immunostaining and FISH analysis.
Second, we present a novel cell sorting system that interrogates over 10 million individual events
each second, resulting in a high throughput, ultra-efficient rare cell sorter that delivers enriched
cells in a vial, readily compatible with virtually any downstream assay. This is the first system
combining the high sensitivity and single cell resolution that is characteristic of FACS with the
practicality of MACS at a throughput and specificity afforded by inertial focusing, enabling
operation in both 'positive selection' and 'negative depletion' modes. We find greater than 90%
cell isolation efficiencies with over 2.5 log depletion of contaminating WBCs. Furthermore, the
system is applied to clinical patient samples, and proof-of-concept is demonstrated in a cohort of
breast, lung and prostate patients.
Working in a negative depletion mode to isolate target cells in an unbiased fashion, we used the
system to assess single putative CTCs isolated from an endogenous pancreatic mouse model for
gene expression of tumor markers. Initial data confirms CTC heterogeneity at the single cell
level, and positions us to move forward with single cell transcriptome sequencing, which may
reveal a broad array of CTC phenotypes including metastatic precursors.
Thesis supervisor: Mehmet Toner
Title: Helen Andrus Benedict Professor of Biomedical Engineering
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Chapter 1: Introduction
Since the association of an imbalance in "black bile" with cancer by the Greek physician Galen
in ancient Rome, to the post-mortem observation of tumor-like cells in the blood in 1869 by
Ashworth, to the validation of circulating tumor cells (CTCs) as a prognostic tool in the early
2000's, the scientific community has had an ever-deepening interest in understanding these rare
cells and their role in the deadly metastatic process. (Figure 1) (1-3) CTCs are exceedingly rare
cells found in the whole blood of cancer patients. They have the potential to serve as a 'blood
biopsy', enabling population-wide screening for early diagnosis, highly sensitive prognostic
monitoring for cancer patients, and serial non-invasive molecular profiling to bring the science of
personalized medicine to practical fruition in the clinic. Furthermore, while much has been
hypothesized about their potential role in the hematogenous dissemination of cancer, the
biological characterization of these cells could lead to an entirely new class of therapies targeting
metastasis.
Figure 1. The potential role of circulating tumor cells in metastasis
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Metastasis is the spread and growth of tumor cells from the primary site to distant organs, is
arguably the most devastating and deadly attribute of cancer, and is ultimately responsible for
90% of cancer-related deaths, resulting in over 500,000 deaths each year in the United States
alone. As discussed, circulating tumor cells have the potential to be highly informative with
regards to our understanding of metastasis. Present technologies, however, enable only a susbset
of potential analyses to be conducted, principally due to sub-optimal cell isolation sensitivity,
purity, throughput, or handling method. Thus, the goal of this thesis is to address the challenge of
CTC isolation by improving on existing techniques or developing new enrichment methods to
enable a wide variety of endpoint analyses of CTCs. (Figure 2)
Patient Blood CTC Isolation CTCs Endpoint Analyses
tmnunnstain
FISH
S, Tchnooq Sequence
Figure 2. Current and potential downstream endpoint analyses of CTCs. Adapted from (4)
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1.1 Thesis overview
This thesis presents two novel technologies that addresses current challenges in CTC isolation.
Chapter 2 first reviews existing rare cell enrichment technologies, including bulk
immunomagnetic approaches, density-gradient isolation, and size-based separation methods as
well as newer microfluidic affinity-based systems.
Chapter 3 presents a biofunctional sacrificial hydrogel coating for microfluidic chips that enables
the highly efficient release of captured cells following gel dissolution. Such a coating is
important because microfluidic systems for affinity-based cell capture have emerged as a
promising approach for the isolation of specific cells from complex matrices (i.e., circulating
tumor cells in whole blood). However, these technologies remain limited by the lack of reliable
methods for the innocuous recovery of surface captured cells. The covalently crosslinked
alginate biopolymer system discussed in chapter 3 is stable in a wide variety of physiologic
solutions (including EDTA treated whole blood) and may be rapidly degraded via backbone
cleavage with alginate lyase. The capture and release of EpCAM expressing cancer cells from
whole blood using this approach was found to have no significant effect on cell viability or
proliferative potential and recovered cells were demonstrated to be compatible with downstream
immunostaining and FISH analysis.
Chapter 4 presents a novel cell isolation technology: Magnetophoretic Inertial Microfluidcs for
Integrated Cell Sorting (MIMICS) - a cell sorting system that interrogates over 10 million
individual events each second, resulting in a high throughput, ultra-efficient rare cell sorter that
delivers enriched cells in a vial, readily compatible with virtually any downstream assay. This is
the first system combining the high sensitivity and single cell resolution that is characteristic of
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FACS with the practicality of MACS at a throughput and specificity afforded by inertial
focusing, enabling operation in both 'positive selection' and 'negative depletion' modes. Whole
blood is loaded into the three-component integrated system which enables (1) lossless sample
debulking, (2) specific cell positioning and (3) highly sensitive magnetophoretic separation of
target cells. In chapter 4, we demonstrate the operating parameters of each system component
and then evaluate the performance of the integrated system for rare cell enrichment, finding
greater than 90% target cell isolation efficiencies with over 2.5 log depletion of contaminating
WBCs. Furthermore, the system is applied to clinical patient samples, and proof-of-concept is
demonstrated in a cohort of breast, lung and prostate patients.
Chapter 5 presents an initial application of the MIMICS system aimed at deepening our
fundamental understanding of CTC heterogeneity. The system was modified to work with an
endogenous mouse model of pancreatic cancer and used in the negative depletion mode to isolate
CTCs in an unbiased fashion. This application was validated using a cell line derived from the
model, and recovery efficiencies were determined to be greater than 95% with approximately 3
log removal of contaiminating WBCs. This high recovery efficiency and low contamination,
along with the relatively high number of CTCs found in the endogenous mouse model, results in
an extremely high sample purity. We were thus able to individually micromanipulate putative
CTCs and, following RNA extraction and cDNA amplification, assess individual cells for
expression of potential CTC markers using qPCR. Interestingly, we observed a spectrum of
expression, from cells expressing only a single keratin marker, to ones robustly expressing three
keratins, to cells expressing no keratins but instead the pancreatic specific gene product PDX1.
This initial data confirms CTC heterogeneity at the single cell level, and positions us to move
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forward with single cell transcriptome sequencing, which is expected to reveal a broad array of
CTC phenotypes.
Chapter 6 summarizes the contributions presented in this work and highlights the critical next
steps to advance the biomaterials technology discussed in Chapter 3, development of the
MIMICS technology discussed in Chapter 4, and the fundamental biological characterization of
CTCs enabled by the work in Chapter 5.
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Techniques for CTC Identification
2.1 Introduction
A wide variety of technologies for CTC identification have been developed over the past 30
years to address the challenge of rare cell detection. (Figure 3) These range from non-enrichment
based strategies, to enrichment strategies based on cells' physical properties, to those based on
antigen expression.
Figure 3. Approaches for circulating tumor cell capture. Adapted from (5).
2.2 Non-enrichment detection
One approach to identifying CTCs centers on detection without the need for selective
enrichment. (6) In a recent embodiment of this approach, an 'HD-CTC' assay was developed.
Here, RBCs are lysed in whole blood and nucleated cells are plated on specially coated glass
slides at a density of ~ 3M cells / slide. The slides are then stained with anti-cytokeratin and anti-
CD45 antibodies, scanned using a custom laser scanning microscope, and automated image
processing software identifies positive targets for further human review. (7) The notable
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advantage of this approach is that it is not reliant on any particular CTC feature for cell isolation,
however the lack of enrichment limits its applicability to imaging-based analyses as the high
numbers of hematogenous cells prevent molecular analyses.
2.3 Size based sorting
A number of technologies have been developed to isolate CTCs from whole blood based on their
presumed larger size as compared to RBCs and WBCs. (8) Two examples of this approach
include a microfabricated porous filter-based device and a shear-modulated inertial microfludics
approach. In the filter-based device, a parleyne membrane with 8 micron pores is sandwiched
between two PDMS slabs, and whole blood is pushed through the membrane. Cote et. al.
demonstrate that larger cultured tumor cells are retained in the pores, while the bulk of WBCs
and RBCs pass through and are collected on the other side of the filter. (Figure 4) (9)
Figure 4. (A) A schematic of the microfilter device with (B) uniform 8 urn pores that (C) retain
larger cultured tumor cells. Adapted from (9).
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Microfluidic approaches for sized-based separation are also being developed. Briefly, inertial lift
forces may be used to create a cell-free zone in the center of the channel, by pushing all cells to
two streamlines along the channel walls; larger cells are then pushed into the center stream as a
result of flowing through a series of contraction-expansion regions that 'pinch', causing the
center of inertia of these cells to align with the central flowstream. (10)
2.4 Density based approaches
Density gradient centrifugation across a Ficoll medium is commonly used to fractionate whole
blood. This technique has been used to enrich disseminated tumor cells (DTCs) from bone
marrow, and has further been adapted to enrich CTCs from blood. (11) The commercial product
OncoQuick relies on similar principles (Figure 5); literature reports indicate over 600 fold
depletion of mononuclear white blood cells from whole blood using this approach. (12)
Figure 5. Overview of OncoQuick technology.
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2.5 Immunological sorting techniques
Antigen based strategies are amongst the most compelling and commonly used for CTC isolation
because they enable highly sensitive and specific targeting of particular cell populations. In
particular, EpCAM (Epithelial Cell Adhesion Molecule) is a classically targeted cell surface
marker in the CTC field as it is broadly expressed across epithelial tumors. Recently, however,
additional disease-specific target antigens have gained prominence including EGFR, HER2 and
PSMA.
2.5.1 Immunomagnetic strategies
The only FDA approved CTC isolation technique, CellSearch, is based on the application of a
bioferrofluid to whole blood. The anti-EpCAM ferrofluid is used to label EpCAM expressing
CTCs, and these cells are then magnetically separated. Importantly, the entire process is
automated, from blood processing to the downstream staining, imaging, and potential target
identification. Strict review guidelines are established for human review of putative CTCs to
ensure that similar scoring techniques are used by all operators. While CellSearch has been
clinically validated as a prognostic indicator, its utility is limited as the endpoint is essentially
binary ( > or < 5 CTCs / 7.5 mL). (1) Alternative immunomagnetic strategies have also been
proposed; these similarly rely immuno-targeting of potential CTCs with a magnetic payload
followed by binding to a magnetic substrate or deflection by a magnetic circuit. (13) Finally,
similar strategies have been used for 'negative depletion' applications, where WBCs are
magnetically tagged and removed from the sample, revealing a spectrum of rare non-
hematogenous cells. (14) These immunomagnetic approaches are promising approaches for rare
cell isolation, but are limited by their sensitivity as they often rely on bulk RBC-lysis methods
which are inherently lossy. (15)
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2.5.2 Microfluidic surface capture approaches
Over the last 5 years, our group has created and developed microfluidic affinity based chips to
capture circulating tumor cells from whole blood; during this time we developed first a
micropost chip (the 'CTC-Chip') and then a second generation chip (the 'HB-Chip'). (Figure 6)
(16-18) Both manipulate the flow kinetics of complex solutions such as whole blood to allow
sensitive detection of CTCs. In the first-generation CTC-Chip, whole blood was processed
through a field of approximately 86,000 microposts, increasing the frequency of cell-surface
interactions. (16) This technology was demonstrated to isolate CTCs in large numbers and with
high frequencies, and additionally enabled the detection of EGFR mutations in lung cancer
patients. (16, 19) However, the HB-Chip is more readily scalable and operates across a broader
range of flow rates; also, in initial studies, the HB-Chip revealed the presence of CTC
microclusters in patient blood. The herringbone chip is centered on the concept of passive
mixing of blood through the generation of microvortices to increase cell-surface interactions. For
cells traveling in a traditional flat microchannel, the laminar uniaxial flow restricts the degree of
interaction between the cells and the antibody-coated capture surface; whereas, for cells traveling
in the herringbone CTC-Chip, the grooves in the upper surface of the device generate helical
flows that stretch and fold volumes of fluid over the cross section of the channel, effectively
mixing the solution. As a result, the cells 'jump' the flow streamlines and consequently interact
significantly more with the antibody-coated surface.
In our initial study evaluating the HB-Chip, samples from 15 prostate patients and 10 healthy
donors were processed. Automated analysis of all samples for PSA+/CD45- cells found a median
of 1 CTC / mL in healthy donors, and 63 CTCs/mL in patients. CTCs were found in 14 of 15
cases (93%), with counts ranging from 12 to 3,167 CTCs/mL. (18) As the first generation CTC-
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chip detected CTCs in 64% of patients when evaluated using the same criteria, the herringbone
clearly performs as well or superior to the initial technology while also revealing CTC
microclusters and potentially enabling further biological insights. (17) Yet, these technologies
remain limited by the inability to elute captured cells for further downstream analysis.
Figure 6. SEM images of the first generation micropost CTC-Chip (left) and the second
generation herringbone HB-Chip (right). (16, 17)
2.6 Summary
A myriad of techniques have been developed for circulating tumor cell (CTC) detection, each
with its own advantages and weaknesses. Non-enrichment strategies are amongst the most
passive as they do not require prospective sorting, however they are limited to imaging based
readouts, given the lack of purification. Size and density based approaches rely on assumed
properties of CTCs; while sorting based on physical properties is reliable, little characterization
of patient CTCs has been conducted to validate these assumptions. Immunological sorting
techniques are arguably the most prominent of current approaches, and both bulk
immunomagnetic sorting and microfluidic surface-based cell capture technologies have
demonstrated reliable CTC isolation from a wide range of clinical samples.
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A Biopolymer System for Cell Recovery from
Microfluidic Cell Capture Devices
3.1 Introduction
Continuous flow affinity-based microfluidic devices are emerging to fill an important niche in
cell sorting. (16, 20) These technologies focus on coating a surface with a capture moeity and
then utilize microfluidic architectures to precisely control and maximize cell-ligand interactions.
(17, 21, 22) The label-free nature of these techniques enables the isolation of cell populations
from complex solutions (i.e., whole blood) with minimal or no pre-processing. This allows for
the rapid isolation of a wide variety of clinically relevant cell types, ranging from exceedingly
rare circulating tumor cells,(17) to CD4+ T cells,(23) to more prevalent neutrophils.(24, 25) At
present, only limited downstream analysis (most commonly, imaging-based approaches) may be
conducted due to the inability to reliably elute viable cells from the microfluidic chips. For
genetic analyses, mixed cell populations must be lysed on chip(19) and only limited amounts of
material can be recovered, restricting the ability to do full genome wide studies of rare cell
populations. Furthermore, the cells are unavailable for downstream purification, differentiation
of complex sub-populations, single cell genomic analyses, or subsequent culture in vitro or in
animal models.
3.2 Background
Cells initially captured on immuno-affinity substrates via specific antibody-antigen binding are
likely to form other non-specific linkages with the surface over time. These non-specific linkages
may confound any molecular release mechanisms which cleave only specific antibody linkages. (
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Figure 7) Potential approaches for the release of surface captured cells range from chemical
methods such as gradient elution to mechanical approaches such as the application of high shear
stress and the use of bubbles within capillary systems.(26, 27) Both chemical and mechanical
approaches have the potential to cause significant harm to the target cell populations. Even if cell
integrity is preserved, the ability to extract phenotypic and functional information from target
populations may be compromised as variations in chemical microenvironments and shear stress
are known to cause significant changes in gene expression patterns. (28)
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Figure 7. Nonspecific cell surface interactions confound targeted cell release mechanisms
In limited studies, the combination of a proteolytic enzyme and surfactant enabled the release of
captured cells for immediate enumeration(29-31); the degradation of surface markers and
potential membrane disruption due to the surfactant, however, may limit the feasibility of this
approach for downstream biological analyses of target cells.
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Phase-changing hydrogels, such as temperature(32) and UV sensitive gels,(33) have emerged as
a potential method to regulate cell-surface interactions. Recently, Hatch et. al.,(34) demonstrated
that ionically crosslinked hydrogels formed in situ enabled the capture, release, and FACS
analysis of endothelial progenitor cells from heparinized whole blood. Notably, this study
demonstrated the feasibility of a cation-crosslinked sacrificial hydrogel approach for microfluidic
cell capture and release without enzymatic digestion of cell surface proteins. This system, while
promising, has a limited scope of use as it cannot be used in conjunction with common anti-
coagulation strategies that work on the principle of calcium chelation (EDTA, citrates, etc).(35,
36) Furthermore, during cell release, target cells are exposed to nonphysiologic levels of calcium
chelating agents which may initiate unwanted signaling cascades within the target cells, and have
the potential to alter the observed cell phenotype and proliferation state.(37-39)
3.3 Approach
Here we present a photocrosslinked, degradable biopolymer coating that enables the gentle,
efficient release of antibody-captured cells from microfluidic devices (Figure 8). Our coatings
are of controlled thickness, stable for extended periods of time, and may be used with a wide
variety of buffers and physiological fluids (including EDTA-treated whole blood). The release
mechanism we employ is the backbone degradation of our alginate biopolymer by a specific
bacterial enzyme (alginate lyase) which is commonly used in combination with cell cultures. (40-
42) We further demonstrate that released cells are viable and proliferative.
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Cell capture on functional hydrogel. Cel release via gel dissolution.
Figure 8. Sacrificial hydrogel coatings may be a compelling strategy for cell release from
microfluidic devices, as they will release both specific and non-specific cell-surface linkages.
3.3.1 Biomaterial selection
Alginate is a naturally derived biomaterial isolated from brown algae that is used across a broad
spectrum of applications, from food processing to cell culture. Within the biomedical
community, alginate occupies a unique niche due to a number of favorable properties.(40)
Alginate is a cytocompatible, non-fouling biomaterial that is generally regarded as safe (GRAS)
by the U.S. FDA. A linear polysaccharide, alginate is composed of repeating mannuronic and
guluronic acid monomers which form its backbone; this structure contains a readily
functionalizable carboxylic acid on each monomer. (Figure 9) Alginate is often selected for
various applications, most notably cell encapsulation, because of its ability to gently form
temperature independent gels via divalent cation (generally calcium) crosslinking under
physiologic conditions.(40) This crosslinking is thought to occur due to an 'eggbox' coordination
between the divalent ions and the carboxylic acids, but the exact mechanism is not well
understood.(40) The gelation is reversible by chelation of the crosslinking cation. Alternatively,
alginate gels may be rapidly degraded by alginate lyase, a bacterial enzyme which specifically
degrades the biopolymer's backbone and should have no affect on mammalian cells (Figure
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9).(41) Alginate lyase has been well characterized and used for many in vitro and in vivo alginate
systems.(42) This degradation strategy enables the dissolution of covalently crosslinked alginate
films, overcoming the limitations of ionically crosslinked systems.
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Figure 9. Structure of alginic acid polymer indicating backbone cleavage site of the enzyme
Alginate Lyase.
3.4 Methods
3.4.1 Alginate modification
Pharmaceutical grade alginate (Pronova UP MVG, Novamatrix, Norway, 60% guluronate, 40%
mannuronate) was modified with both N-(3-Aminopropyl)methacrylamide HCl (Polysciences
21200-5) and biotin hydrazide (Sigma B7639) using standard carbodiimide chemistry in a single
reaction. Briefly, alginate was prepared at 1% by weight in MES buffer, pH = 6.0. Per 100 mL
of alginate solution, 0-159 mg of biotin hydrazide, 225.63 mg of methacrylamide, 721 mg of 1-
Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC, Pierce 22980), and 408 mg
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of hydroxysulfosuccinimide (Sulfo-NHS, Pierce 24510) were added and reacted for 3 hours,
after which time the solution was dialyzed against dH20 for 48 hours and lyophilized. Alginate
was reconstituted at 2% in dH20 prior to use.
3.4.2 Hydrogel formation
Substrates were pre-treated with a molecular-scale layer of alginate by first aminating the surface
with a solution of 3-aminopropyltriethoxysilane (Pierce 80370, in 95% Ethanol, pH=5.0 for five
minutes) followed by reacting the amine-surface overnight with a dilute alginate solution (0.1%
in MES, pH = 6.0) containing 3.73 g of EDC and 2.11 g of Sulfo-NHS per 100 mL. Substrates
were then rinsed and dried prior to spincoating. Alginate solutions were spun (spincoater WS-
650SZ-6NPP/LITE, Laurel Technologies) at 3000 RPM for 30 seconds to control gel thickness,
unless otherwise noted. Gels were then crosslinked using a 250 mM calcium chloride spray,
followed by incubation in a 2.5 mM calcium solution, addition of the photoinitiator irgacure
2959 (Ciba Specialty Chemicals) (0.25%) to the solution, and then photocrosslinking in a
nitrogen environment for 10 minutes using a 365 nm UV lamp (UVP XX-15-BLB). Following
crosslinking, the gels were washed to remove calcium and dried prior to use.
3.4.3 Patterning and functionalizing gels inside simple microfluidic geometries
Gels were spatially templated onto ultraclean glass slides (Thermo C22-5128-M20) by first
applying a laser-cut elastomeric stencil in the shape of the microchannel on top of the glass prior
to hydrogel formation. Following gel formation as described above, the stencil was removed,
and a PDMS microchannel was plasma treated for 30 seconds (ElectroTechnic Products BD-20)
and bonded around the hydrogel.(23) The PDMS microchannels used in this study were
rectangular chambers 50um tall, 4mm wide, and 50 mm long, fabricated using standard soft-
lithography techniques.(43) The channels were flushed with PBS (rehydrating the gels), blocked
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in a 1% BSA solution for a minimum of 30 minutes (blocking the gel and PDMS walls), and
functionalized with neutravidin (Pierce 31000, 50 ug/mL in 1% BSA) for 45 minutes. The
channels were rinsed with PBS and incubated with a biotinylated anti-EpCAM antibody (R&D
Systems BAF960, 20 ug/mL in 1% BSA for 45 minutes) when used for cell capture. In this
model system, only the bottom surface of the channel was coated with the hydrogel, limiting the
available area for cell binding.
3.4.4 Hydrogel characterization
Hydrogel thickness was measured using a non-contact profilometer (Olympus LEXT OLS3100)
after films were formed and dried. To characterize gel dissolution, 50 nm green fluorescent beads
(Duke Scientific G50) were mixed into the alginate solution prior to gelation and thus
impregnated in the resulting hydrogel; as the gel dissolved, beads were released and cleared
away and the decrease in fluorescent signal intensity was monitored using time-lapse imaging.
Initial steady-state intensity measurements were taken before treating the gel with alginate lyase
at a particular concentration, and a final steady-state measurement was taken once the gel had
fully degraded; these values were treated as 100% (initial) and 0% (final) relative intensities. For
the control condition (0 ug/mL alginate lyase) all intensites were compared to the initial steady-
state, as the gel did not degrade; the slight drop in intensity was observed to be caused by
photobleaching of the sample by comparing the intensity of the gel immediately adjacent to
exposed field of view. The experimental samples were observed to rapidly degrade, and so no
notable photobleaching was observed.
Relative biofunctionality was measured using a sandwich assay in which the biotin incorporated
into the hydrogel was coupled with neutravidin, rinsed with PBS, and then followed by a
fluorescent biotinylated protein (biotin R-PE, 20 ug/mL for 45 min in 1% BSA, Life
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Tecnologies). The 'standard chemistry' is a silane-based coupling chemistry used in our
laboratory to functionalize microfluidic devices with neutravidin; it was followed by the same
biotin R-PE solution to assay the biotinylated protein binding capacity of the surface.(16)
3.4.5 Cell capture, release and recovery
Cell capture and release was characterized using both a prostate cancer (PC3) and breast cancer
(SKBR3) cell line. All cell lines were obtained from ATCC and cultured in accordance with their
recommendations.
The relative cell capture efficiency was evaluated by patterning gels in 10 x 10 mm squares and
functionalizing with the anti-EpCAM antibody as described. PC3s in PBS buffer were then
spotted onto the areas in a static capture assay to compare the relative cell capture potential of
the functional alginate coatings as compared to the standard chemistry (positive control, set to
100%) and nonfunctional alginate (negative control). Following a brief incubation period,
unbound cells were removed by gently washing the area with PBS. Cells were counted before
and after washing to determine capture efficiency. This static assay evaluates the effect of
surface ligand presentation on cell capture efficiency, separate from the effects of the
microfluidic geometry. Together, these two parameters determine cell capture efficiency in
affinity-based microfluidic cell isolation devices.
To evaluate performance of the hydrogel system for cell release and recovery efficiency, a model
system was employed; briefly, PC3s were spiked into whole blood (106 cells/mL, notably higher
than the CTC load found in patient samples) and captured in a microfluidic in which the bottom
of the channel was coated with an anti-EpCAM functionalized hydrogel. After PC3s were
captured (2 uL / min) and blood was rinsed out with PBS (20 uL / min), the channel was imaged
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and the total number of cells bound on the gel was counted. Alginate lyase (Sigma A1603, EC#
4.2.2.3, which targets the P-(1-4)-D-mannuronic bonds on the alginante backbone, 1 mg / mL in
PBS) was then flowed through the channel (0.5 uL / min), releasing the cells which were
recovered in an 8-well chamber slide and counted again. The ratio of cells recovered to cells
captured was used to determine the recovery efficiency. The capture areas were re-imaged to
confirm recovery efficiency by verifying the mass balance.
Cell release was observed under a fluorescent microscope (Nikon TiE, Japan) by first pre-
labeling the cells with a dye (CellTracker Red, Life Technologies). Time-lapse images were
taken every 200ms and then analyzed using the tracking module within the manufacturer's
software (Nikon Elements) to chart cell movement as a function of time during the release
process.
3.4.6 Analysis of released cells
Recovered cell viability was measured using a standard live/dead fluorescent assay (Life
Technologies L3224) and compared to control cells which were never introduced into the
microfluidic system. Colony formation was measured by recovering PC3 cells from a spiked
sample and then diluting the cells with culture medium to form a single cell culture environment.
After 96 hours, the number of colonies formed in the well were evaluated alongside the number
of colonies formed from a similar number of control cells. HER2 amplified SKBR3 breast
cancer cell line cells were captured and released in a similar fashion, cytospun, and then
immunostained for the HER2 protein using a primary (Dako rabbit a-Erb2 A0485) secondary
(Alexa Fluor 488 donkey a-rabbit, Life Technologies) antibody staining approach. Released
SKBR3 cells were also probed with HER2 and centromere FISH probes using standard methods.
In brief, released cells were cytospun and fixed with methanol-acetic acid (3:1), washed with 2X
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SSC, dehydrated in an ascending series of ethanol, and a HER2/CEP-17 probe mix was added.
DNA was then denatured at 75oC, hybridized at 37oC for 20 hours, and post-hybridization
washes were performed in 0.4X SSC / 0.3% NP-40 at 72*C for 2 min and 2X SSC / 0.1% NP-40
at room temp for 30 seconds. The samples were counterstained with mounting medium
containing DAPI and imaged at 60X.
3.5 Results and discussion
3.5.1 Biomaterial development and characterization
Carboxyl groups on pharmaceutical grade alginate were modified using standard carbodiimide
chemistry to present both methacryl groups (65% theoretical derivitization) and biotin moieties.
(0-12% theoretical derivitization). The methacryl groups covalently crosslink the alginate to
form a stable hydrogel, and the biotin imparts the bulk material with a ligand for further
biofunctionalization. (Figure 10) Methacryl conjugation was confirmed by conducting proton
NMR using a similar analysis to that performed by Jeon.(44) (Figure 11)
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Figure 10. Here, we developed an alginate (green) biopolymer system which may be covalently
crosslinked using methacryl groups (red) and biofunctionalized using biotin moeities
incorporated in the base material (blue). The gel dissolution and subsequent cell release may be
achieved by brief exposure to the bacterial enzyme alginate lyase which cleaves the backbone of
the biopolymer.
40
b b d2o alginate a a C
Figure 11. Proton NMR validation of alginate acrylation. The vinyl protons marked 'b' indicate
the acrylation of the alginate polymer backbone.
Biotinylation was measured using a modified HABA assay. Alginate was degraded using
alginate lyase (1 mg/ mL) for one hour before proceeding. This degradation enabled
standardization and reproducibility of the assay; samples assayed without degradation formed
visible aggregates in the wells. Figure 12 shows the correlation between theoretical modification
(as a % of carboxyl groups on the alginate backbone potentially derivitized if the reaction went
to completion) and resulting biotinylation as measured using the HABA assay. At 10%
theoretical modification, the measured modification is 5.24%, representing a 52.4% reaction
efficiency.
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Figure 12. HABA analysis of biotinylation as a function of theoretical modification.
To characterize the swelling properties of the derivitized bipolymer, macroscale hydrogels were
formed by photocrosslinking 200uL of 2% alginate solutions with a range of methacryl
substitution (25-75%). As demonstrated in Figure 13, solutions with 25-35% theoretical
derivitization did not fully photocrosslink and did not form stable gels. The equilibrium swelling
ratio was measured for gels formed with alginates with 45-75% acryl substitution by measuring
the weight of the gel after crosslinking, and after immersion in PBS for 24 hours, similar to
approaches used by others.(45) As expected, gels with lower crosslinking had higher swelling
ratios.(46)
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Figure 13. Swelling ratio of alginate gels formed with various degrees of methacrylation.
3.5.2 Hydrogel integration for microfluidic cell capture
As the microfluidic geometry of the channel is critical to maintaining the appropriate shear stress
for cell capture, the thickness and roughness of the alginate layer was carefully controlled using
spin-coating techniques to produce films in the sub-micron regime that would not affect overall
channel fluidics. (Figure 14) The films were photocrosslinked to form a hydrogel which was
stable in the presence of calcium-chelating anticoagulants (i.e., EDTA) but could be rapidly
degraded with the addition of alginate lyase (Figure 15).
43
Figure 14. Alginate hydrogels were formed with micron-scale thickness using a spincoating
process (* p = 0.017; ** p <0.001).
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Figure 15. Upon treatment with alginate lyase at various concentrations (50 (red), 100 (green),
250 (purple), 1000 (orange) ug/ mL, control PBS (blue) ), photocrosslinked hydrogels rapidly
degraded in a dose-dependent fashion.
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To ensure optimal ligand accessibility, a nanopatterning approach was employed similar to that
developed by Comisar et. al.(47, 48) Here, highly biotinylated alginates (86 biotins per chain)
were mixed in solution with non-biotinylated ('blank') alginates.- These biotinylated alginate
chains coil in solution to form nano-islands of functionality spaced apart by blank alginates.(47)
Optimal island density was studied by varying the ratio of biotinylated chains to blank chains in
the copolymer preparation; neutravidin was used to crosslink the gel bound biotins with a
biotinylated capture ligand, thereby presenting the capture ligand on the surface. (Figure 16)
Figure 16. Schematic of 'sandwich' modification approach using neutravidin (orange) to
crosslink a biotinylated antibody to the biotinylated alginate backbone.
This approach demonstrated an inverse trend in which lower bulk average biotin density in the
gel correlated with higher ligand presentation. (Figure 17) Ligand presentation equivalent to that
achieved with the silane-based chemistry commonly employed within microfluidic devices (16,
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23) ("standard chemistry") was realized with 5 to 10 bulk average biotins. (Figure 17) Static
cell capture experiments validated the ligand presentation results; gels functionalized with an
anti-EpCAM antibody captured EpCAM expressing prostate cancer cells at a comparable
efficiency to that of the standard chemistry. (Figure 18)
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Figure 17. Gels were functionalized using gel-bound biotins, and an inverse trend between bulk
biotin density and functionality was observed.
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Figure 18. A static cell capture assay (D) demonstrated that the functional material (blue)
captured cells with an efficiency comparable (* indicates p = 0.45) to standard surface
modification approaches (green), while non-functional gels (red) resisted physisorbtion of
capture molecules and non-specific cell binding (** indicates p < 0.001).
3.5.3 Release and characterization of isolated cells
To convey the gentle nature of the cell release process, a typical captured cell was imaged during
the release process and the position of the cell was tracked over time. (Figure 19) This data
demonstrates how, as the gel is degraded, a captured cell (A) first gradually detaches from the
substrate, (B) then moves slowly along the surface (C) before being caught up in the flow stream
which moves it downstream at the bulk fluid velocity. The efficiency of this cell release process
was evaluated by directly quantifying cell capture, release, and recovery. This study
demonstrated a 99% ± 1% release efficiency.
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Figure 19. Cells from a prostate cancer cell line were spiked into whole blood, captured on an
anti-EpCAM functionalized alginate gel, and released by dissolving the gel with alginate lyase.
The progression of a typical cell during the release process (blue) was tracked using automated
image processing software. Images A-D show the cell at various stages of the release process and
mark the initial location of the cell with a white dashed circle. This series demonstrates the
gentle nature of the release process as the cell starts (A) attached, then (B) slowly detaches and
(C) travels along the surface until (D) it enters the free flow stream, now traveling at the average
bulk velocity of the fluid in the channel (red dotted line). Scale bars are 10 microns. Cells
(n=15) from 3 different gels were tracked during release to determine the average interval
between initial movement to final release.
Released cells were characterized for their viability (98.9% ± 0.3%) compared to control cells
simply spiked into whole blood (99.4% ± 0.6%) and found to be unaffected. (Figure 20A,E)
Similarly, effects of the capture and release process on cell proliferation was studied by diluting
released cells in culture medium and measuring the extent of single cell colony formation after
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96 hours (69.3% ± 3.4%) as compared to similar control cells (68.8% ± 2.2%). (Figure 20B,E)
As an initial demonstration of the compatibility of the release technology with downstream
biological assays, breast cancer cells harboring amplified HER2 genes were spiked into blood,
captured, released, and evaluated using standard immunostaining and fluorescence in situ
hybridization (FISH) techniques. Expression of the HER2 surface receptor was found to be
comparable to control cells (113% ± 21.2% relative intensity). (Figure 20CE) Furthermore,
HER2 gene amplification is readily evident by FISH, illustrating the potential broad applicability
of this cell release technology to enable standard molecular diagnostic applications in a variety of
clinical specimens. (Figure 20D)
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Figure 20. Released cells were evaluated for (A) viability and (B) colony formation; scale bars
are 50 um. Released cells were compatible with downstream (C) immunostaining of cell surface
receptors (HER2 expression in a released cell shown in green, counterstained with DAPI nuclear
staining in blue; 20 umn scale bar). (D) FISH analysis in a released HER2 (green probe) amplified
breast cancer cell is shown (control probe in red). (E) Released cells (blue bars) were found to
have comparable viability, rates of colony formation from single cells, and relative surface
receptor expression when compared to control cells (gray bars) ( p > 0.05).
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3.6 Conclusions
The alginate biopolymer system presented here represents an important step forward in
developing affinity-based cell capture surfaces as it enables gentle, efficient recovery of isolated
cells without compromising their viability or proliferative potential. The critical followup of this
work is the development of precisely controlled coating techniques for the integration of this
materials approach with the complex microfluidic architectures used for rare cell isolation.(16,
17, 19, 29) While existing technologies have demonstrated their clinical relevance, recovering
these cells with high efficiency and in an unadulterated fashion will place them in the hands of
molecular and cell biologists in a manner that is readily compatible with their arsenal of
sophisticated tools, so that we may begin to further elucidate the roles of these cells in human
biology.(1, 4, 49)
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Whole Blood Magnetophoresis for Circulating
Tumor Cell (CTC) Isolation
4.1 Introduction
Over the past 30 years, numerous technologies have been developed to address the CTC
enrichment challenge, including bulk immunomagnetic approaches, density-gradient isolation,
and size-based separation methods. (8, 13, 14, 50, 51) Although these technologies have
established the potential prognostic utility of CTCs, albeit with poor sensitivity, the bulk
handling and manipulation techniques (including RBC lysis) required pose an inherent danger of
losing rare and fragile tumor cells. (1, 52) Furthermore, mixed reports on the physical size and
morphology of CTCs reduces confidence in size-based filtration methods for enrichment. (8, 17,
53) More recently, microfluidic surface-based techniques have grown in prominence as they
facilitate lossless cell handling; these approaches have enabled CTC isolation from whole blood
without any pre-processing, resulting in increased efficiencies. (16, 17, 25) Isolated cells,
however, often remain bound to the substrate and are not directly compatible with downstream
analyses. While this limitation may be potentially addressed using the technological approach
presented in the previous chapter, microfluidic surface capture techniques are fundamentally
limited to positive enrichment modalities, as the area required to capture all contaminating RBCs
and WBCs makes operating in a 'negative-depletion' mode impractical. Non-enrichment based
strategies have the potential to identify interesting rare cell populations, however the lack of
purification severely limits molecular analyses. (7)
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Chapter 4:
Advancement in our understanding of CTCs has been limited, chiefly due to the lack of a robust,
highly sensitive, universal CTC enrichment technology that is compatible with the needs of cell
biologists, molecular geneticists, and classical pathologists. This requires a high-throughput (>
mLs / hour) system with a high degree of sensitivity (efficiency) and specificity (purity) as CTCs
represent only 1 in 108 cells in whole blood. The central biological hurdle facing development is
that the limited understanding of this heterogeneous cell population results in a poorly defined
"target" to isolate - creating the need for a universal system that can be rapidly tuned to sort
various cell populations; such a system could sort cells in a "positive enrichment" fashion to
answer defined questions about particular populations, while also enabling a "negative
depletion" mode in which hematogenous cells are depleted, exposing the underlying rare cell
biology. Finally, enriched CTCs must be presented in a manner that is conducive to application
in defined in vitro and in vivo culture models, the analytical techniques employed in modern
molecular biology, as well as conventional cytopathology.
4.2 Approach
Here we present Magnetophoretic Inertial Microfluidcs for Integrated Cell Sorting (MIMICS) - a
cell sorting system that interrogates over 10 million individual events each second, resulting in a
high throughput, ultra-efficient rare cell sorter that delivers enriched cells in a vial, readily
compatible with any downstream assay. This is the first system combining the high sensitivity
and single cell resolution that is characteristic of FACS with the practicality of MACS at a
throughput and specificity afforded by inertial focusing, enabling operation in both 'positive
selection' and 'negative depletion' modes. Whole blood is loaded into the three-component
integrated system which enables (1) lossless sample debulking, (2) specific cell positioning and
(3) highly sensitive magnetophoretic separation of target cells. (Figure 21) Whole blood is mixed
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with immunomagnetic beads and first processed through a post array which deflects nucleated
cells into a buffer stream; the cells are then precisely aligned and ordered in the center of a
second microchannel using inertial focusing techniques, and the magnetically tagged cells are
displaced to the channel wall using an external magnetic field.
RBCs, platelets, other
blood components.
Blood
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Figure 21. The overall process flow for the integrated cell enrichment system is described. (left)
Immunomagnetic beads are mixed with whole blood to tag cells intended for deflection. The
HCS array isolates nucleated cells from smaller blood components such as RBCs, platelets, and
free magnetic beads. These nucleated cells enter the inertial focusing and magnetophoresis
channels where they are focused to a central stream and then magnetically labeled cells are
separated. The two system inputs are whole blood and a running buffer; system outputs include
the waste of HCS array, non-deflected cells, and deflected cells. The system runs in an integrated
modality wherein the HCS product is connected directly to the focusing channels. This
continuous cell separation mode improves both the throughput and system reliability while
minimizing parasitic cell losses.
Using EpCAM-based positive selection, low expressing cells were enriched with exceedingly
high efficiency (> 90%) and purity (- 5 log removal of contaminating cells); lossless enrichment
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of ultra low EpCAM expressing cell lines from whole blood was achieved through negative
depletion of WBCs. High-speed microfluidics allow bulk-scale throughput (~8ml whole blood /
hour), while precise localization of cells to a center streamline enables single cell resolution
sorting, resulting in exquisite sensitivity and specificity. Continuous, sheath-less operation
enables large volumes (>15ml) to be processed without hindering system performance. Using
this system, we demonstrate that CTCs may be isolated from patient blood samples and analyzed
using both advanced molecular approaches and traditional cytopathological techniques.
4.3 Methods
4.3.1 System design
The overall system is driven by a pressure source which pushes the running buffer and whole
blood into the HCS array. (Figure 22) The waste outlet is connected to a syringe pump which
withdraws the waste solution containing RBCs at a volumetric flow rate approximately 3 fold
greater than the HCS product flow rate. This ratio, as well as the driving pressure selected (18-21
PSI), is used to ensure the purity of the HCS array product and maintain the flow rate needed to
achieve optimal function. The HCS array product, containing leukocytes and putative CTCs, is
connected to the magnetophoresis channel, which deflects cells above the magnetic threshold to
a single outlet. Undeflected cells are collected via another outlet.
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Figure 22. Overview of the entire MIMICS system and processor.
4.3.2 Cell culture
MDA-MB-231, SKBR3, and MCF10A cell lines were obtained from ATCC (Manassas, VA),
PC3-9 cells were a gift from Veridex, LLC, and LBX1-expressing MCF10A cells were derived
from a stable cell line previously developed and published by our laboratory.(54) All cells were
cultured and propagated in accordance with providers recommendations and maintained in
humid, 37*C, 5% CO2 cell culture incubators. As noted for specific experiments, cells were
prelabeled with a fluorescent tracer dye (CellTracker Red or CellTracker Green, Life
Technologies, USA) following the manufacturer's recommended protocol.
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4.3.3 Whole blood
Fresh whole blood was collected from healthy volunteers under an approved Institutional Revew
Board protocol or commercially sourced from Research Blood Components (Watertown, MA).
4.3.4 Microscopy
All fluorescent microscopy was conducted using either inverted or upright microscopes (TiE or
Eclipse 90i, Nikon, Japan) with the appropriate filter cubes for the respective stains.
4.3.5 HCS array design and fabrication
The hydrodynamic cell sorting (HCS) array is designed to efficiently separate nucleated cells
from other blood contents, in a high-throughput and continuous operation. The array relies on the
deterministic lateral displacement principles previously described.(55-57) Each of the 20 parallel
channels has two input streams that run side-by-side in laminar flow, one consisting of the
running buffer (1% F68 Pluronic in PBS, Sigma P1300), and consisting of the whole blood to be
separated. The blood is introduced into an array of microposts (active area: 500 um wide by 22
mm long by 150 um high per channel; single post diameter of 150 um; 24 channels per chip) and
enters at a small angle (~1') relative to the array, such that the leukocytes, which are large with
respect to the flow streamlines, are displaced out of the streamline when they encounter a post.
By contrast, the enucleated components of the blood (RBCs, platelets, plasma) follow the
streamlines predicted by laminar flow theory, unperturbed by the array. By the end of the array,
nucleated cells have been sufficiently deflected into the buffer stream, separating them from the
rest of the blood. Two different array configurations were designed at MGH and fabricated by
Silex (Norway) using deep reactive ion etching (DRIE), HCSIe.k. and HCS_. The gaps
between posts (g) are 20 and 32 um respectively, the center to center distances between the posts
(k) are 35 and 56 um respectively, and the row shift fraction (E) is 0.16 for both designs. (Figure
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23) The chip is sealed with an anodically bonded glass cover and mounted in a custom
polycarbonate manifold to connect the macroscale tubing to the microscale channels.
A: Obstacle Spacing
a: Row Shift Fraction
g: Gap
Figure 23. Schematic of an HCS array depicting key parameters
4.3.6 Magnetophoresis chip design and fabrication
The chip relies on inertial focusing of cells in a microfluidic channel, followed by magnetic
deflection of magnetically labeled cells from the focus stream to a stream at the edge of the
channel. The chip was designed and fabricated at MGH using standard soft lithography
techniques. (43) The channels are 50 um high and consist of 3 distinct regions: an inlet region
with filters, a focusing region and a deflection region. The inlet filters are needed to prevent
downstream clogging of the focusing channels and have a gap size of 30 um. The focusing
region consists of 60 asymmetric serpentine curves with a width of 50 um and a connecting
curve with maximum width of 95 um. (Figure 24, left) In the deflection region, the channel
expands to a 500 um width, to reduce the flow speed of cells in the channel, therefore increasing
the residence time of cells in the magnetic field. The chip splits into either 2 outlets (positive
selection) or 3 outlets (negative depletion) that separates the deflected and undeflected cells.
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(Figure 24, center and right) The chip is placed within a custom stainless steel manifold that
holds 4 magnets in a quadrapole configuration to create a magnetic circuit enabling cell
deflection. (Figure 25)
~: Inlet from HCS Array
hwntil Focusing and
MgnetophorelIs Channels
Focusing Region Outlet Region(Positive Selection)
Outlet Region
(Negative Depletion)
Excess Buffer
Undeflected Cells
Asymmetric Focusing Curves Undeflected Cells
Deflected Cells
Deflected Cells
Figure 24. Schematic of the inertial focusing and magetophoresis channels, depicting (top)
overview, (left) focusing region, (center) outlet configuration for postive selection, and (right)
outlet configuration for negative depletion.
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Figure 25. Schematic indicating the position of the 4 permanent magnets placed in a manifold to
create a quadrapole magnetic circuit, relative to the magnetophoresis channel.
4.3.7 HCS array characterization
To demonstrate the size-based separation principle, 2pm (red) and lOym (green) polystyrene
microspheres were combined into a single solution and flowed through the 'blood' inlet of an
HCS chip. The chip was imaged in four distinct locations from the inlet to the exit of the chip.
To characterize the performance of the two HCS arary designs, whole blood samples (n > 10)
were processed through each chip, and the starting blood as well as outlet product and waste
solutions were analyzed to quantify nucleated cell retention, RBC removal and platelet removal.
Analysis was conducted using a Sysmex KX blood analyzer, or for dilute solutions, by staining
nucleated cells with Hoescht dye and determining their concentration using a Nageotte chamber.
Dilute RBC concentrations were determined by counting all events in brightfield and subtracting
the number of nucleated events detected using the Hoescht stain. Additionally, product and waste
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collected from whole blood processed through an HCSncer array was analyzed using a coulter
counter (Beckman Coulter X-X, USA) to illustrate the size-based nature of the separation from
whole blood.
4.3.8 Magnetophoresis characterization
4.3.8.1 Characterization with magnetically tagged and untagged Cells
To demonstrate magnetic cell sorting, red fluorescent SKBR3 cells labeled with EpCAM coated
magnetic beads were mixed with non-labeled green fluorescent stained PC3-9 cells. This
mixture was flowed through the IFM chip and imaged at various locations.
43.8.2 Evaluation of critical variables on streak quality
To characterize the effects of critical variables on cell focusing, solutions with various
concentrations of WBCs and RBCs were prepared by processing whole blood through an HCS
chip and labeling the WBCs with calcein AM (1 uM, Life Technologies, USA). Samples were
then diluted to achieve the desired concentration and RBCs were added as needed to achieve the
desired hematocrit. They were then processed through the IFM chip and imaged at l0x using
long exposure times (~ 5 seconds) to collect a fluorescent streak image that represents the
position of >1000 individual events at the end of the deflection region. A line-cut across the
image is taken and signal intensity across the channel was measured. (Figure 26) Commercially
available curve fitting tools were used to determine the full-width-half-maximum (FWHM) of
the streak image, and streak quality was defined as (Channel Width / FWHM); the tighter the
focus stream, the smaller the FWHM, the greater the streak quality.
60
0 100 200 300 400 500
Position across channel (pm)
Figure 26. Performance of the inertial focusing components was assessed by analyzing a (inset)
long exposure fluorescence image. A linecut was taken across the image, and the (panel) signal
intensity was plotted and fit to a Gaussian distribution.
4.3.9 Quantitative modeling of cell deflection
Finite element modeling (FEM) was conducted using commercially available software
(COMSOL) to calculate the magnetic gradient created in the deflection channel by the
quadrapole magnetic circuit depicted in Figure 25. Second order effects due to position in the z-
dimension or edge effects at the beginning or end of the deflection region (y-dimension) were
not considered. The fluid velocity profile in the deflection region was also determined using
FEM based on 2D modeling, given the bulk-average flow rate and channel dimensions.
The results of the FEM modeling of the magnetic gradient and fluid velocity profile, the
empirical measurement of cell position based on streak imaging, estimates of CTC size, and the
properties of Dynal MyOne beads as reported in the literature were integrated to develop a
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quantitative model of cell deflection. (58) Briefly, cells were considered to be in the center of the
focused stream upon entering the deflection region, and their position was iteratively calculated
based on the assumed bead loading, resulting deflection in the x-direction and travel down the
channel in the y-direction (due to fluid velocity). This model was then used to determine the
minimum magnetic load needed to deflect a cell into the 50um region by the channel wall, as a
function of the bulk flow rate; an expected range was calculated based on the distribution in cell
size as well as initial focus position.
The model's outcome was experimentally validated by preparing samples spiked with PC3-9
cells with a spectrum of bead labeling; these samples were then processed through the chip at
various flow rates and bead loading on PC3-9 cells recovered in the deflected and undeflected
solutions was quantified. Curve fits were applied to these distributions, and the intersection of
the deflected and undeflected distributions was taken to represent the 'minimum magnetic load
needed for deflection'.
43.10 Labeling target cells in whole blood
Target cells were labeled in whole blood using Dynal MyOne streptavidin magnetic beads (656-
01, Life Technologies, USA) coupled with biotinylated antibodies per the manufacturers
recommendations.
Beads were added in whole blood and mixed using either passive or active approaches. In
passive mixing, the samples underwent end-over-end rotation for 15 minutes (positive selection)
or 60 minutes (negative depletion). For positive selection, active mixing was employed by
bringing the sample tube in contact with a magnet for 30 seconds, removing the magnet, rotating
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the tube 180* around its long axis, and bringing it back in contact with the magnet; this cycle was
repeated continuously for 7 cycles. (Figure 27)
30 sec. 30 sec. 30 sec. 30 sec.
Gently Rock
2 minute cycle
Figure 27. Depiction of the Active Magnetic Mixing (AMM) procedure
Labeling of target cells was determined as a function of beads added per WBC. For positive
selection, pre-labeled cell lines with low and high EpCAM expression (MB-231 and SKBR3)
were doped into whole blood, incubated with various amounts of anti-EpCAM (BAF960, R&D
Systems, USA) coated beads, and samples were mixed using either active or passive mixing.
Following mixing, samples were processed through an HCS chip to remove RBCs and collected
in a 24 well plate; target cells were identified based on their fluorescence and bead loading was
evaluated. For negative depletion, whole blood samples were incubated with various
combinations of anti-CD45 and anti-CD15 (BAM1430, MAB7368 (biotinylated in house), R&D
Systems, USA) coated beads and passively incubated for 60 minutes. Samples were then RBC
lysed (BioLegend 420301, used per manufacturer's protocols) and stained with Hoescht dye to
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accurately identify nucleated cells. Bead loading was evaluated on > 100 nucleated events in
each sample.
4.3.11 Evaluation of integrated system
Five cell lines with a wide range of EpCAM expression were used to evaluate rare cell
enrichment efficiency in the integrated system. EpCAM expression levels were measured using
flow cytometry. Briefly, pure populations of each cell line were prepared in suspension, stained
with either the biotinylated goat anti-EpCAM antibody used for cell isolation or a biotinylated
irrelevant IgG (BAF108, R&D Systems, USA), rinsed, and labeled with a fluorescent avidin
secondary stain. After labeling, the samples were rinsed, fixed, and evaluated using standard
single-color flow cytometry. (MACSQuant, Miltenyi Biotec, USA) Analysis was conducting
using commercial flow cytometry software (FlowJo, USA) and the median fluorescence value
for each EpCAM-stained cell population was compared to the respective IgG control.
Performance of the integrated system was evaluated by pre-labeling the cell lines described with
a fluorescent marker and spiking them into whole blood at low concentrations (~ 1000 / mL
whole blood). The samples were then incubated with magnetic beads, processed through the
integrated system, and rare cell yield was quantified using a mass balance approach. The
depletion of nucleated cells was quantified by measuring the initial WBC concentration (Sysmex
KX Analyzer, Sysmex, USA) and comparing to the final WBC concentration, measured by
staining nucleated cells using Hoescht and counting in a nageotte chamber. For positive
selection, anti-EpCAM beads were added at a concentration of 300 ug beads / mL whole blood
(~ Y beads / WBC, assuming 5M WBC/mL), and incubated with whole blood using active
magnetic mixing for 15 minutes. For negative depletion, anti-CD45 and anti-CD15 beads were
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added at a 100:50 ratio per WBC, and incubated using end-over-end passive mixing for 60
minutes.
4.4 Results and discussion
4.4.1 Hydrodynamic cell sorting (HCS) array
Building on established design principles, we developed two HCS arrays: HCSCekO deflects
virtually all (99.7% ± 0.4%; De=2.6 um) nucleated cells into the product stream with minimal
contaminating RBCs (< 0.1%), as well as HCS . which has a larger hydrodynamic size cutoff
(De=3.8um), deflecting -60% of nucleated WBCs (Figure 28, Figure 29). (55-57)
Figure 28. The hydrodynamic size based sorting that occurs in the HCS array is demonstrated
here. A mixture of fluorescent 2 pm (red) and 10 pm (green) beads enter the channel (1) and
while the 2 p m beads remain in laminar flow in the top channels, the 10 p m spheres interact with
the post array (2-3) shown in the SEM and are fully deflected into the adjacent buffer stream by
the end of the array (4)
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HCS Array Type HCSm HCSWjg
Nucleated Cell Retention 59 19.0 % 99.7± 0.4 %
RBC Removal 99.97 t 0.03 % 99.94 1 0.03 %
Platelet Removal 100t0% 100t0%
Figure 29. Both the HCSce, and HCSeuko designs demonstrate the ability to separate nucleated
cells from RBCs in whole blood. Although a crude approximation of hydrodynamic cell size,
coulter counter measurements of product and waste from a sample processed through the
HCScac array are presented to demonstrate the size-based nature of the deterministic separation
process.
Granulocytes, with their lobular flexible nuclei, have a notably smaller hydrodynamic radius than
mononuclear WBCs; standard flow cytometry characterization confirms that the WBCs being
removed by our HCSe., array are principally granulocytes and small lymphocytes. (55) (Figure
30) Importantly, the chip retains all nucleated cells above 8 um in size as well as 100% of each
of the 5 different tumor cell lines we evaluated.
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Figure 30. A whole blood sample (input) was processed in parallel through both versions of the
HCS array, and the resulting products were collected. These samples were then compared to the
input sample (after RBC lysis) using standard flow cytometry; gating based on accepted
forward/side scatter characteristics was used to approximate the fraction of neutrophils,
monocytes, and lymphocytes in each sample. As demonstrated, the HCS.C. array retains fewer
neutrophils and lymphocytes than the HCSIe.Ck array.
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4.4.2 Inertial focusing to control cell position
The system relies on both the inertial ordering of cells within a microfluidic channel, as well as
their magnetic loading to enable cell sorting via magnetophoretic deflection of tagged cells to the
channel wall. (Figure 31)
Inertial
focusing inlet filters
I nlet
Manetic deflection region
Figure 31. The cell focusing and magnetophoretic sorting features are demonstrated here.
Magnetically labeled (red) and unlabeled (green) cell poulations were mixed and enter the
channel at random (1). After passing through 60 asymmetric focusing units (pictured in the
SEM), the cells are aligned in a single central stream (2). Magnetically tagged cells are then
deflected (3) using an external magnetic field, and full separation is achieved by the end of the
channel (4).
To control the position of cells in the X-Z plane, we rely on inertial focusing principles
previously discovered in our laboratory. (59) Here, we characterized the operating regime to
understand the effects of flow rate, cell concentration and background RBC concentration on
nucleated cell focusing in the deflection region as inter-particle interactions increase when the
fluid slows upon entering. As presented below, the optimal flow rate was determined to be 100
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uL / minute. (Figure 32) Streak quality was determined to be acceptable for solutions with
nucleated cell concentrations below 3M / mL and an effective hematocrit below 0.5%. (Figure
33, Figure 34)
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Figure 32. Observed streak quality as a function of flow rate. Below 100 uL / min, streak quality
decreases as inertial forces are not sufficient for optimal focusing. Above this rate, streak
splitting begins to occur and so the focused stream does not maintain a central position.
Figure 33. Streak quality decreases with increasing cell concentration
interactions increase, causing defocusing.
as inter-particle
69
-'3%,.
- 1~J%
-o
= =
I ==0I
I
35
10
5
0
0.2 2
Call Concentration (10')
Figure 34. RBC contamination of the HCS array product has the potential to cause defocusing of
otherwise focused nucleated cells by increasing inter-particle interactions.
4.4.3 Highly sensitive magnetophoresis
As demonstrated, inertial focusing enables precise control over cell position, here centering all
nucleated cells in the middle of the channel. This in turn enables highly sensitive microfluidic
magnetophoresis, as magnetically tagged cells start in the center of the channel and only need to
deflect ~ 200 um to reach the cell-free zone at the channel wall. (Figure 35) Based on the bulk
flow rate, we are able to determine the residence time of a cell in the deflection region to be t,
600 ms. Finite element modeling of the quadrapole magnetic circuit used here yields an estimate
of the magnetic gradient (dB/dx) across the channel to be 150 T/m; combining this information
with the actual fluid velocity profile in channel, we calculate the magnetic payload needed to
successfully deflect labeled cells (assuming a maximum cell diameter of 30 um) to within 50 um
of the channel wall. Based on the magnetic moment of Dynal MyOne beads, we predict that cells
with 15 or more beads will be reliably deflected into the collection stream. (Figure 36)
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Figure 35. Here, the highly sensitive nature of the microfluidic magnetophoresis is depicted. Cell
populations with characterized bead loading were serially processed through the inertial focusing
and magnetophoresis channels, and imaged part of the way down the deflection channel. As
demonstrated, cells with increasing bead loading deflected further towards the side wall.
71
20 X100
20-
1 15 
i
100 50
10
s0 2s5
0 100 200 300 400 500 0 10 200 sW
Position across channel (sm) Position across channel (pum)
Figure 36. A mathematical model was built to understand the deflection of labeled cells (red)
from a focused stream of particles (white). FEM analysis of the quadrapole magnetic circuit
(center left) and fluid flow in the channel provided estimates of the magnetic gradient (blue) and
flow rate (green) across the deflection channel (bottom left). This information, in conjunction
with our experimental understanding of cell position in the focused stream (pink) was used to
construct an overall model to predict the trajectories of focused cells with varying magnetic
payloads (right).
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Given the spread in both cell size and initial position with the focus stream, we are further able to
establish expected cutoff values to define the minimum calculated magnetic load (and
variability) as a function of flow rate. Importantly, this analysis is validated by experimental
measurements. Briefly, cell solutions with varying levels of bead labeling were prepared and
processed at various flow rates (t from 300 to 600 ms); the distribution of bead number on cells
collected in the deflection stream versus the non-deflected stream was analyzed and mirrors
expected results, as the magnetic payload needed to deflect increases with increasing flow rate
(decreased residence time) in accordance with the model. (Figure 37, Figure 38)
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Figure 37. The experimental 'mimimum payload to deflect' was determined by plotting
histograms of bead loading density for deflected and undeflected cells; the intersection of curve
fits of this data was taken to represent this minimum value.
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Figure 38. The analytical model presented in Figure 36 was used to determine the minimum
magnetic load needed to deflect PC3-9 cells as a function flow rate, given the measured
variability in cell size. Importantly, the experimental data presented in Figure 37 concurs with
the predictions.
4.4.4 Multi-modal sorting of CTCs
We used the MIMICS system to explore two modes of immnomagnetic sorting to isolate CTCs
using this system: a positive selection mode wherein target CTCs were identified and tagged
based on their expression of the surface marker EPCAM, and a negative selection mode wherein
the sample was depleted of leukocytes tagged with surface markers CD45 (otherwise known as
common leukocyte antigen) and CD15 (a broadly expressed granulocyte marker).
4.45 Immunomagnetic labeling of target cells in whole blood
For positive selection, while simple mixing of anti-EpCAM magnetic beads in whole blood
enabled sufficient labeling of high EpCAM expressing cells (SKBR3), the addition of Active
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Magnetic Mixing (AMM) was found to dramatically increase the extent of bead-cell interactions
and was necessary to achieve sufficient magnetic labeling of low EpCAM expressors (MB-231).
(Figure 39)
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Figure 39. For immunomagnetic positive selection, anti-EpCAM magnetic beads were mixed
with whole blood spiked with either MB-231s (square) or SKBR3s (circle). The use of active
magnetic mixing (filled symbols) was necessary to achieve optimal labeling of very low EpCAM
expressing MB-231 cells.
For negative depletion, while CD45 is the gold-standard leukocyte marker, a combination of
beads targeted against CD45 and CD15 was needed to achieve sufficient labeling of the sample.
Given the heterogeneity of CD45 expression on leukocytes, and the known low expression of
CD45 on granulocytes, this was determined to be the appropriate secondary marker. (Figure 40)
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Figure 40. For immunomagnetic negative depletion, a combination of anti-CD45 (targeting all
WBCs) and anti-CD15 (targeting granulocytes) beads is necessary to label ~ 100% of the target
WBCs.
4.4.6 Performance of integrated system for rare cell isolation from whole blood
To evaluate the efficiency of CTC purification, 5 cell lines with dramatically varying EpCAM
expression were spiked into whole blood isolated using positive or negative selection modes.
(Figure 41)
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Figure 41. EpCAM expression of five model cell lines.
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With the advent of AMM and the high sensitivity of the MIMICS technology, very low EpCAM
expressing cells (MB23 1) could be isolated with greater than 70% efficiency, and low expressing
EpCAM cells commonly used as model CTCs (PC3-9s) were isolated with greater than 90%
efficiency. A model of EMT induction in traditionally high EpCAM expressing MCF10A cells
previously developed in our group resulted in a cell line (LBX1) with ultra-low EpCAM
expression; in the negative depletion mode, we were able to isolate both these cells and the
parental MCF1OAs with high efficiency, demonstrating the benefits of an EpCAM-independent
sorting mode. (54) (Figure 42)
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Figure 42. Overall system performance was evaluated using 5 cell lines of varying EpCAM
expression (Figure 41). As expected, EpCAM based positive isolation efficiency was dependent
on EpCAM expression level, however PC3-9 cells (orange) traditionally considered low EpCAM
expressors are isolated with an efficiency greater than 90%. Encrichment through negative
depletion was independent of EpCAM expression.
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Sample purity varied notably between operating modes - in positive EpCAM based selection, a
purification of over 3.5 log was achieved (1495 average contaminating WBCs/mL input); in
negative selection, a purification of 2.5 log was achieved (31,838 average contaminating
WBCs/mL). (Figure 43) Importantly, the isolated cells are presented in suspension, enabling
direct compatibility with virtually all downstream analytical techniques.
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Figure 43. While enrichment through negative depletion was independent of EpCAM expression,
this approach has an order of magnitude lower purification when compared to positive selection,
demonstrating the tradeoff between these complementary approaches.
4.4.7 Isolation and characterization of CTCs from patient samples
In an initial cohort of breast, prostate, and lung cancer patients, we demonstrate the clinical
application of the MIMICS technology to enable isolation of patient CTCs. In the following
series of figures we demonstrate the use of 'positive selection' for isolation of PSA+ PSMA+
80
CTCs and for the identification of the EML4-ALK translocation CTCs enriched from known
mutant lung cancer patients. (Figure 44, Figure 45) We further demonstrate the use of 'negative
depletion' for the isolation of cytokeratin expressing CTCs from a series of ER+/PR+ and triple
negative (TN) breast cancer patients as well as traditional Papanicalaou staining of enriched cells
from these samples; using this classical staining approach, a board certified cytopathologist was
able to identify certain 'suspicious' cells in these samples. (Figure 46 - Figure 54) Finally, we
demonstrate that bulk qPCR analysis of cells isolated using negative depletion from a prostate
cancer patient demonstrates the presence of putative CTC markers at the RNA level when
compared to a similarly processed healthy donor; PSA+ , PSMA+ and dual PSA+PSMA+ CTCs
were identified in this sample by standard immunofluoresence. (Figure 55, Figure 56)
Figure 44. Example of a PSA+/PSMA+ CTC isolated using positive selection from a patient with
metastatic prostate cancer. The sample was stained for DAPI (blue, all panels), PSMA (yellow,
left) and PSA (red, center). The right panel shows co-localization of the PSA and PSMA signals
in the cytoplasm, as well as demonstrating the presence of the EpCAM beads used for cell
isolation.
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Figure 45. The positive selection approach is compatible with sensitive molecular
characterization of enriched CTCs. Here, blood samples from 3 non-small cell lung cancer
(NSCLC) patients with known EML4-ALK translocations was processed using positive
selection; both the 'product' and 'waste' samples were magnetically enriched and DNA was
extracted and probed for the EML4-ALK translocation. As demonstrated, a positive signal was
found in all 3 CTC fractions (ALK61, ALK6, ALK19) and in cell line controls (H3122).
Negative controls and healthy donors were negative. Interestingly, the undeflected 'waste' from
ALK61 and ALK19 were also negative, but the waste from ALK6 (ALK6 w.) was positive,
indicating that there were likely CTCs in this sample with magnetic labeling below the deflection
threshold.
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Figure 46. Identification of a cytokeratin positive (CK+) CTC from a patient with metastatic
breast cancer, enriched using negative depletion. Clockwise from top right, DAPI (blue),
cytokeratin (red), CD45 (green), and merged image.
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Figure 47. CK+ CTC from a patient with metastatic breast cancer, , enriched using negative
depletion. Stained as in Figure 46.
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Figure 48. CK+ CTC from a patient with metastatic breast cancer, , enriched using negative
depletion. Stained as in Figure 46.
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Figure 49. CK+ CTC from a patient with metastatic breast cancer, , enriched using negative
depletion. Stained as in Figure 46.
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Figure 50. CK+ CTC from a patient with metastatic breast cancer, enriched using negative
depletion and stained for DAPI (top right panel), cytokeratin (bottom left panel), and CD45.
Bottom right panel shows all 3 immunofluoresence stains (DAPI, CK, CD45) merged together,
and top left panel incorporates a brightfield image.
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Figure 51. CK+ CTC from a patient with metastatic breast cancer, enriched using negative
depletion and stained for DAPI (top right panel), cytokeratin (bottom left panel), and CD45.
Bottom right panel shows all 3 immunofluoresence stains (DAPI, CK, CD45) merged together,
and top left panel incorporates a brightfield image.
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Figure 52. CTCs were isolated from the blood an ERIPR+ breast cancer patient using negative
depletion and stained using traditional papanicalaou staining. These cells were identified as
'suspicious' and 'consistent with lobular carcinoma' by a board-certified cytopathologist. (60X)
Figure 53. Similarly identified cells from the sample shown in Figure 52, here at 10OX.
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Figure 54. 'Suspicious' cells identified from a patient with triple negative breast cancer using
papanicalaou staining. Sample was prepared using negative depletion.
Putative prostate
CTC markers WBC markers Controls
Figure 55. Fluidigm bulk qPCR analysis of negative depletion product enriched from a prostate
patient's whole blood. This analysis demonstrates increased gene expression for CTC markers
when compared to a similarly processed healthy donor, particularly for PSA (KLK3) and PSMA
(FOLH1).
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Figure 56. Immunoflourescent confirmation of prostate CTCs from the patient sample presented
in Figure 55. Stains include DAPI (blue), PSA (Cy5), PSMA (Cy3), CD45 (FITC). Note that the
punctate FITC staining is due to inadvertent labeling of free magnetic beads with the fluorescent
secondary antibody.
4.5 Conclusions
We have demonstrated that the MIMICS system is a powerful cell isolation technology.
Operable in both positive selection and negative depletion modes, the system is able to process
whole blood at over 8 mL per hour. By harnessing multiple microfluidic technologies, we
couple lossless sample debulking with highly sensitive magnetophoresis, resulting in in-line CTC
sorting from whole blood at a rate of over 10 million events per second with high efficiency and
specificity. Furthermore, using clinical samples, we demonstrate that putative CTCs may be
analyzed using both standard Papanicalaou staining and bulk transcriptome analysis. The ability
to study CTCs in such detail with classic morphological stains and sophisticated molecular
approaches has the potential to greatly further our understanding of these rare cells.
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Single Cell Analysis of CTCs from an Endogenous
Pancreatic Mouse Model
5.1 Introduction
Pancreatic cancer is the fourth leading cause of cancer-related death in the United States
estimated to be 34,000 deaths for 2008. Moreover, median survival of metastatic pancreatic
cancer patients is only 3-6 months at present. Most patients present with surgically unresectable
disease on diagnosis, and although many different systemic therapies have been tried, their
efficacy has been limited. Therefore, it is essential that the mechanisms of pancreatic cancer
metastasis are more clearly understood so that better therapies may be developed. To further
elucidate these mechanisms, here we apply the MIMICS system presented in the previous
chapter to isolate putative CTCs from an endogenous pancreatic mouse model; target cells are
enriched in an unbiased fashion using the negative depletion approach and presented for single
cell transcriptome analysis and characterization.
5.2 Background
5.2.1 Pancreatic cancer biology
Pancreatic ductal adenocarcinoma (PDAC) comprises the majority of all pancreatic cancers and
appears to progress from three precursor lesions: pancreatic intraepithelial neoplasias (PanIN),
mucinous cystic neoplasm (MCN), and intraductal papillary mucinous neoplasm (IPMN). (60)
(Figure 57) PanIN is the most common precursor lesion and in humans it undergoes multiple
molecular events to develop into PDAC. A very early event in PDAC initiation is the
development of an activating mutation in the oncogene K-RAS. The K-RAS oncogene is a GTP-
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binding protein that is involved with a number of cellular processes including differentiation,
proliferation, and survival. Activating mutations occur at codon 12 and can be found in nearly
all advanced PDAC (61). PDAC malignant progression is further modulated by inactivating
mutations or deletions of the tumor suppressors p16", p 4",ARF p53, and/or SMAD4. The tumor
suppressor p53 is mutated in a number of different malignancies and occurs in 50-75% of PDAC
through point mutation and loss of heterozygosity (61). Importantly, mutation of p53 has been
linked with both genetic instability and metastasis in PDAC in the mouse models (62).
94
Nomal duct
I
Later Events MCN
P53 loss
SMAD4/DPC loss
(BRCA2/ LKBI)*
Pancreatc
Adenocarcin -M
Figure 57. Development of Pancreatic Ductal Adenocarcinoma (PDAC). Adapted from (60)
5.2.2 Mouse models of pancreatic cancer
All of these genetic alterations have been engineered into mouse models developed through the
conditional mutation of Kras and concurrent knockout of each of the above tumor suppressors
using a Cre-lox system (63-65). These established systems harbor common genetic aberrations
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found in human PDACs and provide a robust system to evaluate the effects of tumor genetics to
the phenotype of the primary tumor, metastases, and CTCs.
Comparative analyses between these sites of tumor cells can reveal features unique to CTCs.
This type of analysis is not possible in humans since primary and metastatic lesions are not often
removed in patients as part of therapy. Differences found in genetic or molecular profiles
between these tumor cells may provide unique insights into the pathogenesis of metastasis,
provide a foundation for human pancreatic CTC investigations, and expose new strategies to
develop therapies against this otherwise incurable disease. In fact, such studies recently
conducted within our group using a murine analog of the HB-Chip implicated non-canconical
Wnt signaling in pancreatic cancer metastasis. (66) Briefly, an endogenous KrasG12 D/Tp53'"ox+or lox
driven PDAC murine model was studied, and found to produce CK+ CTCs in 7/8 tumor-bearing
mice. (Figure 58, Figure 59)
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Figure 58. Representative image of tumor size observed in a KrasG12D/Tp53'"+Or'Ox driven PDAC
mouse model at approximately 6 weeks of age.
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Figure 59. CTCs isolated from endogenous tumor-bearing mice using a modified HB-Chip.
Immunostaining was used to identify CK+, CD45- cells as CTCs. Adapted from (66)
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These CTCs were captured on the chip and, along with contaminating WBCs (reported purity
0.1% - 6%), lysed to extract RNA. Using single molecule RNA sequencing, bulk CTC
transcriptome analysis was conducted by splitting blood samples from tumor bearing mice and
processing through anti-EpCAM and sham IgG functionalized chips and digitally subtracting the
matched NSB leukocyte reads. By identifying transcripts overexpressed in the CTC-enriched
samples and comparing to mouse and human primary tumors, Wnt2 was identified as a prototype
CTC-enriched transcript. A detailed study of the role of Wnt2 in pancreatic cancer indicated that
expression suppresses anoikis, enhances anchorage-independent sphere formation, and increases
metastatic propensity in vivo. Importantly, Yu and Ting also demonstrate that it may be
suppressed by inhibition of the Map3k7 (Tak1) kinase either with short hairpin RNAi or with a
small molecule inhibitor 5-Z-oxozeanol. (66) This study demonstrates the potential for molecular
analysis of CTCs to unearth novel therapeutic targets to address metastasis.
5.2.3 Heterogeneity in CTCs
Recent work in our group and others has revealed a significant heterogeneity within circulating
tumor cells isolated from a single patient. (4, 7, 18, 67) At a coarse level, this is demonstrated by
the presence of both proliferative (Ki67+) and apoptotic (M30+) CTCs in prostate cancer
patients. (4) (Figure 60) Moreover, in a small cohort of prostate patients, an elevated fraction of
Ki67+ CTCs appeared to correlate with castration resistant disease, whereas a depressed fraction
of Ki67+ CTCs appeared to correlate with a castration-sensitive phenotype. (18)
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Figure 60. Demonstration of CTC heterogeneity as a mixture of proliferative (Ki67+) and
apoptotic (M30+) CTCs were found in prostate cancer patients. Adapted from (4)
Heterogeneity may also be seen along a different axis. In malignancies of epithelial origin, there
is strong evidence linking an Epithelial-to-Mesenchymal Transition (EMT) to the metastatic
cascade and the development of cancer stem cell (CSC) like features. (67, 68) It has been further
suggested that CTCs may contain subsets of such cells undergoing EMT and potentially
responsible for forming metastases. In fact, in a study being conducted by our group focused on
breast cancer CTCs isolated using the HB-Chip, RNA-ISH analysis has revealed the presence of
CTCs with a range of epithelial and mesenchymal properties. (68) (Figure 61) Together, this
evidence supports the assumption that CTCs in fact are a heterogeneous cell population.
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Figure 61. Demonstration of CTCs (identified based on the presence of epithelial markers) with
varying epithelial and mesenchymal marker expression. (68)
5.3 Motivation
The identification of Wnt2 as a potential tumor-associated marker by bulk analysis of CTC
enriched transcriptomes, and the subsequent validation of this target demonstrates the potential
for CTCs to be highly informative with regards to metastasis. However, the current platform
utilized by Yu and Ting is limited not only by a bias towards EpCAM expressing CTCs as a
result of the positive-selection nature of the technology, but also because it depends on a pooled
analysis of all CTCs. (66) This potentially masks the presence of exquisitely unique cells in the
CTC population that may express high levels of important transcripts (i.e., stem cell or EMT
markers) that are more biologically relevant to metastasis. Therefore, in order to be able to fully
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explore the range of CTC transcriptomes, a platform that allows for unbiased CTC enrichment
and subsequent single cell analysis is needed.
5.4 Approach
This project is focused on applying the MIMICS enrichment technology described in the
previous chapter to enable unbiased CTC isolation from endogenous PDAC models and
subsequent single cell transcriptome analysis, with the goal of more clearly revealing CTC
heterogeneity and potential novel CTC-associated transcripts. (Figure 62) The negative depletion
technology described in the previous chapter is modified here to work with mouse blood
samples, and the approach has been validated using both a murine PDAC cell line, as well as an
orthotopic model. CTCs were isolated from endogenous tumor-bearing mice and immunostained
for cytokeratin and CD45 to further validate the application of this enrichment system in the
murine model. A portion of each enriched sample was also plated in a dish and potential CTCs
were individually selected using a micromanipulator, and subsequently underwent RNA-
extraction and cDNA amplification. Each single cell product was then screened using qPCR for
putative CTC markers, including the pancreatic specific transcript PDX1 as well as a number of
cytokeratins and CD45 (a leukocyte marker) as a negative control. At this stage, a profile of CTC
heterogeneity began to emerge, validating the technological approach undertaken. Selected
samples will now be sequenced and analyzed to further reveal CTC heterogeneity, however the
results of this complex analysis is beyond the scope of the thesis presented here.
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Figure 62. Project Overview. Following CTC enrichment using negative depletion, single
putative CTCs were isolated using a micromanipulator, RNA was extracted, cDNA amplified,
and qPCR was conducted to aid in target identification for downstream transcriptome
sequencing.
5.5 Methods
5.5.1 Mice and cell lines
Mice with pancreatic cancer used in these experiments express Cre driven by Pdx1, LSL-
KrasG12D, and Tp53'ox'+ or Tp53""x" as previously described (64). Normal FVB mice were
purchased from Jackson Laboratory. For cardiocentesis, animals were sedated with isofluorane,
the chest wall was sterilized with ethanol and a skin incision was made above the rib cage. A 23-
gauge needle was used to draw approximately 1 mL of blood into a syringe primed with 100 [tL
of PBS-1OmM EDTA pH 7.4 (Gibco). Blood EDTA concentration was raised to 5mM by either
the addition of a concentrated bolus of 500mM EDTA or 1:1 dilution with 10 mM EDTA.
Animals were then euthanized per animal protocol guidelines.
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A mouse pancreatic cell line (NB508, KrasG12 D/Tp53'ox+) previously generated from primary
tumors developed in this endogenous model was used for spiked cell experiments. For orthotopic
experiments, a GFP-transfected line of NB508 cells was injected into the pancreas of healthy
FVB mice. Both lines were maintained in standard culture conditions using RPMI-1640 medium
+ 10% FBS + 1% Pen/Strep (Gibco/Invitrogen).
5.5.2 Adaptation of CTC enrichment technology
Given the desire for an unbiased enrichment system, the previously presented negative depletion
technology was selected for this application. All processing protocols were identical to those
previously identified, except a rat anti-mouse CD45 antibody (BAM 114, R&D Systems, USA)
was conjugated to MyOne beads.
Spiked cell experiments were conducted to validate the system by spiking ~ 1000 GFP
expressing NB508 cells into 1 mL of healthy mouse blood and processing to determine recovery
efficiency. Orthotopic models were used to validate recovery efficiency as well as initially
determine expected depletion efficiency from tumor-bearing mice. In these experiments,
enriched samples were evaluated for the number of GFP+ cells observed in the product using the
quantitative methods described in the previous chapter.
5.5.3 Immunostaining of CTCs isolated from the endogenous model
Isolated CTCs were spun onto glass slides and immunostained using a primary-secondary
approach. Primary antibodies were rabbit anti-wide spectrum cytokeratin (1:50, Abcam ab9377),
and goat anti-mouse CD45 (1:500, R&D systems AF1 14). Secondary immunofluorescent-tagged
antibodies were used for signal amplification. These were donkey anti-rabbit Alexa Fluor 594
(1:500, Invitrogen A-21207), and donkey anti-goat Alexa Fluor 488 (1:500, Invitrogen A-
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11055). Nuclei were then counterstained with DAPI and the slides were rinsed with PBS,
coverslipped and stored at 4*C. They were imaged under 1Ox magnification using the BioView
Ltd. automated imaging system (Billerica, MA) as well as an automated upright fluorescence
microscope (Eclipse 90i, Nikon, Melville, NY). Positive staining for CK, without CD45 staining,
was required for scoring potential CTCs, which were then manually reviewed. Threshold and
baseline signals were established using specimens from non-tumor bearing mice.
5.5.4 Single cell micromanipulation and transcriptome amplification
After enrichment from whole blood, cells were collected in a petri dish and viewed using an
inverted microscope (Nikon, Melville, NY) outfitted with a hoffman modulation contrast (HMC)
system to improve viewing of live cells. Cells of interest were indentified based on lack of
labeling with anti-CD45 beads, as immunofluoresence analysis indicated that cells with a high
number of attached beads were contaiminating leukocytes. Target cells were individually
isolated using a hydraulic micromanipulator (Eppendorf, Germany) and transferred to droplets
containing RLT buffer and/or flash frozen in liquid nitrogen. Single cell amplification of
individual transcriptomes was conducted using the protocol developed by Tang et. al. (69)
(Figure 63) Following the initial PCR amplification, samples were screened using qPCR for
leukocyte (CD45) and CTC (PDX1, CK8, CK18, CK19) markers to determine which samples
were best suited for sequencing.
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Figure 63. Single cell amplification protocol. Adapted from (69)
5.6 Results and discussion
5.6.1 System modifications to enrich CTCs from mouse blood using negative depletion
The inertial focusing based technology presented in the previous chapter was modified for
application with the endogenous mouse model system. While mice have WBC concentrations
comparable to humans (5-12 M / mL), the distribution amongst various subclasses of WBCs is
notably different. Human hematology reveals a bi-modal distribution, with ~ 50% neutrophils
and ~ 40% lymphocytes, whereas in the mouse, ~ 75% of all WBCs are lymphocytes. As
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lymphocytes express high levels of the CD45 antigen, we evaluated WBC labeling using CD45
alone, rather than combined with a myeloid marker as was found to be needed in the human
system. Additionally, 1:1 dilution of the blood with PBS prior to processing was compared to
labeling in whole blood. As demonstrated in Figure 64, when labeling in whole blood we were
able to achieve ~100% labeling efficiency with CD45 beads alone. The reduced performance
observed with diluted samples is attributed to an increase in volume resulting in reduced bead-
cell interactions. All future experiments were conducted with 100 anti-CD45 beads added per
WBC to undiluted whole blood.
I
S
I4-a
100%
80%
60%
40%
20%
0
0
*Whole blood
0 Diluted 1:1
50 100 150
Number of Bads added per WBC
Figure 64. Labeling of mouse WBCs using anti-CD45 MyOne beads.
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5.6.2 System validation using spiked cells
The enrichment approach performed as expected when modified. GFP labeled NB508 cells were
spiked into healthy mouse whole blood, and were recovered with an efficiency of 97.5%.
Importantly, when compared to the data presented by Yu and Ting on capture efficiency of
NB508 cells using an anti-EpCAM approach (~ 35%), the unbiased method used here is a
notable improvement. (66) This is suspected to be due to the variable expression of EpCAM on
NB508 cells.
5.6.3 Enrichment of CTCs from orthotopic and endogenous tumor bearing mice.
Blood samples from orthotopic mice were collected and processed approximately 2 weeks post-
injection and enriched products were analyzed for GFP+ cells. Blood from endogenous mice was
similarly collected and processed; in these samples, CTCs were indentified based on
immunostaining; healthy controls were also processed to control for artifacts due to staining. As
presented in Figure 65 (left panel) CTCs were found in high numbers in both models.
Importantly, low levels of contaminating WBCs were found in the products, as WBCs were
depleted by over 3 log when compared to the initial blood samples. (Figure 65, right panel) The
combination of relatively high CTC yields and low contamination resulted in sample purities that
were feasible for downstream single cell selection. A selection of cytokeratin positive CTCs
isolated from the blood of endogenous PDAC bearing mice is presented below (Figure 66 - 71).
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Figure 65. CTC enrichment from whole blood obtained from both orthotopic and endogenous
mouse models. (left panel) Significant enrichment was achieved by ~ 3 log depletion of mouse
WBCs. (right panel)
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Figure 66. Representative gallery of CK+ cells identified by BioView imaging platform.
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Figure 67. Cytokeratin positive CTC found in the blood of an endogenous PDAC bearing mouse
stained with DAPI (blue), cytokeratin (red) and CD45 (green).
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Figure 68. CTC identified from an endogenous mouse sample. Stained as in Figure 67.
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Figure 69. CTC identified from an endogenous mouse sample. Stained as in Figure 67.
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Figure 70. CTC identified from an endogenous mouse sample. Stained as in Figure 67.
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Figure 71. CTC identified from an endogenous mouse sample. Stained as in Figure 67.
5.6.4 Single cell transcriptome amplification
To validate the single cell amplification protocol developed by Tang, et. al. in our own hands, 6
single NB508 cells were selected using the micromanipulation techniques described and
amplified. (69) As demonstrated, five of the six transcriptomes successfully amplified, and based
on the qPCR data presented, a threshold Ct value was set at 25 cycles for further analysis.
(Figure 72)
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Figure 72. qPCR Analysis of 6 single NB508 cells indicates 5 of 6 single cells were successfully
amplified. Dashed line at 25 cycles indicates threshold used for further analysis.
5.6.5 CTC Identification by qPCR and initial insight into heterogenity
60 single cells enriched from endogenous samples were analyzed in an initial cohort, and qPCR
was conducted for GAPDH (sample quality), KRT8, KRT 18, KRT19 (cytokeratins traditionally
associated with CTCs), and PDX1 (a pancreatic specific marker). This analysis demonstrated
that 49/60 single cells were successfully amplified, and 24/48 CD45- cells were positive for
cytokeratins. Interestingly 5/48 cells were positive for PDX1, but no keratins, and 19/48 cells
were negative for any of the tested markers, but were successfully amplified (based on GAPDH
signal). This data, along with the variability in keratin expression observed provides an initial
insight into the heterogeneity of CTCs. (Figure 73) Transcriptome sequencing of these single
cells will likely reveal a much more complex picture, and has the potential to identify rare, but
biologically important, subsets of CTCs.
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Figure 73. qPCR analysis of 60 single cells found in CTC enriched samples obtained from
endogenous tumor bearing mice.
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5.7 Conclusions
Here we presented an initial application of the MIMICS system to further our understanding of
pancreatic cancer metastasis. CTCs from an endogenous pancreatic cancer mouse model were
isolated using a modified negative depletion configuration. By optimizing the depletion of
murine WBCs and interrogating the entire blood volume, we were able to recover CTCs in
solution, in large numbers, and with high purity. This enabled single cell micromanipulation and
transcriptome amplification. Initial qPCR analysis revealed broad heterogeneity amongst
putative CTCs, with a range of cytokeratin expression levels and expression of the pancreatic-
specific gene product PDX1. Perhaps most intriguing was the detection of PDX1 expressing cells
with low or absent cytokeratin expression; these cells, found in whole blood, are presumably of
tumorigenic origin yet lack expression of the traditional epithelial cytokeratin markers associated
with CTCs, suggesting they may represent a subpopulation of CTCs undergoing EMT or may be
otherwise implicated in the metastatic process. Ongoing work towards full transcriptome
sequencing of these single cells will likely more fully reveal the heterogeneity within the CTC
population and provide insights into the mechanisms of pancreatic cancer metastasis.
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Chapter 6: Conclusions and outlook
In this thesis, two novel technologies are presented with the overall aim of enabling detailed
characterization of circulating tumor cells with an array of immunophenotyping and molecular
analysis tools.
6.1 Summary of contributions
Initially, we developed a novel biomaterial coating for microfluidic cell capture devices. As
demonstrated, this coating facilitates cell capture with an efficiency comparable to standard
chemistries, while enabling the release of virtually all captured cells upon degradation of the
sacrificial coating. Importantly, the backbone degradation mechanism is innocuous to
mammalian cells, and is demonstrated to have no effect on cell viability or proliferative
potential. By dissolving the entire coating rather than targeting particular linkages, both specific
(antibody-antigen) and non-specific (electrostatic) cell-surface linkages are cleaved, resulting in
highly efficient release of captured cells. This study clearly demonstrated the utility of sacrificial
coatings to enable the release of immunoaffinity captured cells from microfluidic cell capture
devices.
Second, we present an entirely new CTC isolation technology, known as the MIMICS
(Magnetophoretic Inertial Microfluidcs for Integrated Cell Sorting) system. This system
integrates three microfluidic components - lossless debulking of whole blood, precise cell
positioning using inertial forces, and highly sensitive magnetophoresis. As demonstrated, this
system can be used for either positive selection (with > 90% yield of low EpCAM expressing
PC3-9 cells) or negative depletion ( > 90% yield of ultra-low EpCAM expressing LBX1 cells).
The enriched CTCs are collected in solution, and in the case of negatively enriched cells, free of
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any bound labels; this makes them readily compatible with a wide array of downstream assays.
In an initial cohort of breast, prostate and lung patients, we are able to readily indentify CTCs
using standard immunofluoresence methods and molecular profiling. Furthermore, review of
papanicalaou stained samples by a board-certified cytopathologist revealed 'suspicious' and
'aberrant' cells likely of tumorigenic origin. Together, this initial data validates the functionality
of the MIMICS system for CTC isolation from a clinical cohort; it further demonstrates the
potential for highly sensitive, solution-based cell isolation to enable new downstream analyses
which were previously technically limited. Most compelling is the development of a robust,
sensitive 'negative depletion' approach to enable near lossless isolation of non-hematopoietic
cell populations from whole blood, as this has the potential to reveal previously unstudied
subpopulations of CTCs.
The MIMICS system was applied to an endogenous pancreatic mouse model to enable unbiased
enrichment of CTCs, with the goal of better understanding the heterogeneity inherent in this rare
cell population. CTCs were recovered with high purity, enabling single cell micromanipulation
and gene expression analysis. Following single cell RNA extraction and cDNA amplification,
qPCR analysis for a series of keratins (8, 18, 19) as well as PDX1 (a pancreatic specific marker)
and CD45 (a leukocyte marker) was conducted. This initial screen revealed a notable number of
'classical' CTCs with high keratin expression and absent CD45 expression, while also
highlighting a wide array of other phenotypes worthy of deeper characterization. Additionally,
the study further demonstrates the flexibility of the MIMICS system as it was readily adapted to
the mouse model.
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6.2 Recommendations for future work
6.2.1 Sacrificial coatings for the release of immunoaffinity captured cells
The efforts towards release of immuno-affinity captured cells presented in this thesis clearly
motivate the use of a sacrificial layer approach. While the work shown encompasses biomaterial
development and validation, the key step needed to enable CTC capture and release is integrating
the coating with the three-dimensional HB-chip micro-architecture in a conformal fashion. This
is critical, as preservation of the microchip architecture is necessary to enable efficient rare cell
capture. Potential coating approaches that should be explored include spraycoating and
dipcoating; these are both robust, scalable techniques used to deposit biopolymers on substrates.
Alternative approaches to forming sacrificial coatings should also be considered, as they may be
more amenable to conformal coating. For instance, layer-by-layer (LBL) deposition is a well
established method to form conformal hydrogels. (70, 71) By successively depositing polymers
with opposing charges, a hydrogel may be formed as electrostatic forces hold the polymer layers
together. Importantly, each layer is 'self-terminating' and thus conformal coatings may be easily
formed. Another strategy to consider would be polymer vapor deposition; hydrogels formed
using this approach have been demonstrated to conformally coat complex geometries. (72, 73)
Key to the success of either of these approaches will be the selection of polymers and
crosslinkers with rapidly degradable moieties to enable dissolution and cell release.
6.2.2 The MIMICS cell isolation system
The MIMICS system presented in this thesis represents a notable improvement in microfluidic
immuno-based cell isolation. While promising, the system needs to be further validated using a
larger clinical cohort and with direct comparisons to other CTC enrichment strategies, such as
121
the HB-Chip and the CellSearch system. Coupling the system with downstream lossless cell
handling and plating methods would notably improve the utility of the technology. Further
improvements should focus on advancing both the cell capture efficiency and purity. For
'positive selection', this may be achieved by exploring a variety of capture moieties beyond
EpCAM. These could include antibodies or aptamers against disease-specific targets such as
EGFR (lung cancer), HER2 (breast cancer), or PSMA (prostate cancer). Positive selection would
also benefit from increases in purity through targeted removal of contaminating WBCs; possible
approaches could include surface immuno-affinity capture or antibody directed photolysis.
Achieving another order of magnitude of purification in the 'negative depletion' mode would be
an important advancement of the technology; this is imperative to enable molecular analyses of
samples enriched in this manner. Multiple avenues exist to achieve this goal, including fluidic,
magnetic and reagent enhancements. Based on the mathematical model presented previously
(Figure 36), a minimum of 6-8 beads are needed to deflect white blood cells; this calculation,
along with the probabilistic distribution of bead-cell interactions during the labeling process,
suggests that many of the undeflected WBCs are labeled with magnetic beads, but in numbers
below the deflection threshold. These cells could be magnetically removed from the sample
using a secondary purification channel in which the residence time was increased by expanding
the channel cross-section and therefore decreasing the magnetic load needed to deflect. As this
approach would disrupt cell focusing, the WBCs would need to be deflected not to a side stream,
but to the bottom of the channel, where they could be magnetically held in place while the target
cells continued to the outlet. Another strategy to deplete cells with low levels of bead labeling
would be to create a high-gradient magnetic field in the deflection region, thereby decreasing the
magnetic load needed to deflect a cell to the side of the channel in the given residence time.
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High gradient fields have been commonly used in bulk cell isolation technologies, and have
recently been integrated into microfluidic circuits; the major obstacle is the complexity of
patterning and aligning magnetizable materials at the microscale. (74) The third tactic that could
be taken to improve the purity of the negative depletion product centers on modulating the
reagents. While the 1 micron magnetic beads used here have a large magnetic moment, once a
bead is bound to an antigen, surrounding antigens are sterically blocked from binding to
additional beads; given that WBCs express millions of copies of CD45 on their surface, the
effective copy number is dramatically reduced due to this steric hindrance. Therefore, using
much smaller (-50 nm) highly magnetizable particles, which would not block surrounding
antigens, has the potential to increase the overall magnetic loading on a cell. (75) Finally, it
should be noted that while the vast majority of non-tumor cells found in whole blood express
CD45 and CD15, there are other rare cell populations that exist in blood and lack these antigens,
such as megakaryocytes and circulating endothelial progenitor cells; specific targeting of these
cell populations should be considered. Similarly, should characterization of the undepleted
WBCs reveal a specific subpopulation of leukocytes, direct targeting of this subpopulation
through specific antigens would be warranted.
6.2.3 Single cell analysis of circulating tumor cells
The natural extension of the work presented in chapter 5 is full transcriptome sequencing of the
amplified CTCs isolated from the endogenous pancreatic cancer mouse model; such an analysis
has the potential to fundamentally advance our understanding of pancreatic cancer metastasis. If
particular subpopulations of CTCs emerge (i.e., CTCs with stem cell or EMT characteristics),
detailed study of these populations would be warranted. At a minimum, the transcriptome
analysis efforts are likely to identify gene products that are highly expressed in CTCs, generating
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a wealth of potential therapeutic candidates that merit biological characterization. Additionally, it
is anticipated that with improvements in the purity of CTCs isolated from human blood samples
using negative depletion, a similar characterization of human CTCs could be conducted, directly
deepening our understanding of the role of CTCs in a wide variety of human cancers.
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